Taysha Gene Therapies, Inc. (TSHA) SEC Filings & Earnings Calls
EquiReason read 11 Taysha Gene Therapies, Inc. SEC filings in the last 12 months. Latest: 10-Q on 2026-08-11 — Quarterly report with positive clinical data for TSHA-102 and continued operating losses..
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 1.3B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
11 Aug 202610-QQuarterly report with positive clinical data for TSHA-102 and continued operating losses.earningsopen
Figures in the filing · each found in the filing text
| Net loss · H1-2026 | $-89M | |
| Accumulated deficit · 2026-06-30 | $800M | |
| Gross proceeds from equity offerings · cumulative | $1.19B |
Risks flagged
No approved products or revenue
“We do not have any product candidates approved for sale and have not generated any revenue from product sales.” · word for word
Significant operating losses and accumulated deficit
“Our net losses were $89.0 million for the six months ended June 30, 2026. As of June 30, 2026, we had an accumulated deficit of $800.3 million.” · word for word
Dependence on debt financing
“We drew $50.0 million in term loans on the Trinity Refinance Date.” · word for word
Clinical trial and regulatory uncertainty
“The interim analysis to support the planned and FDA-aligned BLA submission is expected to occur after all 17 patients complete six months of post-treatment follow-up.” · word for word
Shareholder derivative lawsuit
“In addition, we expect to incur legal fees in connection with the shareholder derivative lawsuit against certain of our current and former directors in the Court of Chancery of the State of Delaware.” · word for word
11 Aug 20268-K · 2.02Completed dosing in REVEAL pivotal (N=17) and ASPIRE (N=4) trials for TSHA-102 in Rett syndrome; TSHA-102 generally well tolerated with no severe SAEs or DLTs across 33 patients; longer-term data showed broad multi-domain functional gains dopen
Figures in the filing · each found in the filing text
| Cash and equivalents · Q2-2026 | $230M |
Risks flagged
Clinical trial failure pressure: TSHA-102 is the sole pipeline asset; any negative data or regulatory setback could materially impact the company.
“TSHA-102 is the only clinical-stage program; topline data from REVEAL pivotal trial expected in 1H 2027.”
25 Jun 20268-K · 1.01, 8.01Taysha Gene Therapies launched and priced an underwritten public offering of common stock and pre-funded warrants; net proceeds expected to fund operations into H2 2028.open
Risks flagged
Dilution risk from large equity offering.
“Offering of 32.5M shares plus pre-funded warrants.”
22 Jun 20268-K · 7.01, 8.01Taysha Gene Therapies announced completion of dosing in REVEAL pivotal trial and reported longer-term clinical data from Part A of REVEAL Phase 1/2 trials for TSHA-102 in Rett syndrome.open
Risks flagged
Clinical trial risks remain; regulatory approval not guaranteed.
“Forward-looking statements highlight risks including regulatory approval and trial outcomes.”
6 May 202610-QNet loss $-42M; Accumulated deficit $754M; Gross proceeds from equity sales $961Mopen
Figures in the filing · each found in the filing text
| Net loss · Q1-2026 | $-42M | |
| Accumulated deficit · 2026-03-31 | $754M | |
| Gross proceeds from equity sales · inception to 202 | $961M |
Risks flagged
Clinical trial failure risk
“Our lead product candidate is still in the clinical stage. We do not have any product candidates approved for sale and have not generated any revenue from product sales.” · word for word
Capital need risk
“We will need to raise substantial additional capital in the future.” · word for word
6 May 20268-K · 2.02Released earnings results and quarterly financials; filed financial statements and exhibits with this reportearningsopen
Risks flagged
Clinical-stage company with no approved products or revenue; dependent on trial success and regulatory approval.
“Clinical-stage biotechnology company focused on advancing AAV-based gene therapies for severe monogenic diseases of the CNS.” · word for word
22 Apr 2026DEF 14AAnnual proxy statement filed; no material event beyond routine governance and compensation disclosure.open
Figures in the filing · each found in the filing text
| Net Income (Loss) · FY2025 | $-109M | |
| Total Shareholder Return (TSR) · FY2025 | $310.73 | |
| Shares Outstanding · 2026-04-08 | 287,341,999 |
Risks flagged
Accumulated deficit and net losses
“Net Income (Loss) ($ Thousands): 2025 (108,995), 2024 (89,298)”
Dilution from equity offerings
“The total net proceeds from the 2025 Offering were approximately $215.6 million... The table below sets forth the aggregate number of shares of our common stock and pre-funded warrants to purchase shares of our common stock issued to our related parties in the 2025 Offering” · word for word
19 Mar 202610-KNet loss $-109M; Accumulated deficit $711Mopen
Figures in the filing · each found in the filing text
| Net loss · FY2025 | $-109M | |
| Accumulated deficit · FY2025 | $711M |
Risks flagged
No product revenue; reliance on equity and debt financing
“We do not have any product candidates approved for sale and have not generated any revenue from product sales.” · word for word
Astellas option expiration removes potential partnership revenue
“In October 2025, the Rett Option expired without being exercised.” · word for word
19 Mar 20268-K · 2.02Released earnings results and quarterly financials; filed financial statements and exhibits with this reportearningsopen
Risks flagged
Clinical-stage company with no approved products; significant cash burn and reliance on successful BLA submission and commercialization.
“No revenue reported; full-year 2025 financial results; company is pre-revenue.”
4 Nov 20258-K · 1.01, 2.02ATM offering capacity $212M; Prior ATM capacity $150M; ATM sales to date $12Mopen
Figures in the filing · each found in the filing text
| ATM offering capacity · November 4, 2025 | $212M | |
| Prior ATM capacity · Prior to amendme | $150M | |
| ATM sales to date · Through Septembe | $12M |
Risks flagged
Dilution risk from increased ATM capacity
“Increase in aggregate offering amount from $150M to $212M”
Clinical trial risk; pivotal trial not yet initiated
“Dosing of first patient in REVEAL pivotal trial scheduled for Q4 2025” · word for word
4 Nov 202510-QTaysha reported Q3 2025 results: no revenue, net loss of $32.7M, cash of $297.3M, and provided clinical updates including FDA Breakthrough Therapy designation and pivotal trial initiation.earningsopen
Figures in the filing · each found in the filing text
| Cash and cash equivalents · Q3-2025 | $297M | |
| Net loss · Q3-2025 | $33M | +28% y/y |
| Research and development expenses · Q3-2025 | $26M | +72% y/y |
| Accumulated deficit · Q3-2025 | $683M | |
| Net proceeds from May 2025 offering · Q2-2025 | $216M |
Risks flagged
Clinical trial failure risk
“We do not have any product candidates approved for sale and have not generated any revenue from product sales.” · word for word
Capital requirement risk
“We anticipate that we will need substantial additional funding in connection with our continuing operations.” · word for word
Dependence on single product candidate
“Our lead clinical program TSHA-102 is in development for the treatment of Rett syndrome.” · word for word
Taysha Gene Therapies, Inc. — questions
- What did Taysha Gene Therapies, Inc. file recently?
- 11 SEC filings in the last 12 months. Latest: 10-Q on 2026-08-11 — Quarterly report with positive clinical data for TSHA-102 and continued operating losses.
Every figure on this page comes from Taysha Gene Therapies, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.